A current grasp of GLP-1 receptor agonists for addiction: emerging therapeutic potential

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists have gained prominence for their role in managing type 2 diabetes and obesity. Recently, their potential in addressing substance use disorders has attracted significant interest. GLP-1 receptor agonists exert effects on reward-related neural pathways, suggesting their utility in modulating addiction-related behaviours. This article examines the mechanisms through which GLP-1 receptor agonists impact on addiction, summarises preclinical and clinical studies, and explores their therapeutic potential for abuse of substances such as alcohol, nicotine, opioids and stimulants. Despite promising findings, challenges remain, including understanding optimal dosing, long-term safety and individual variability. Future research directions are outlined to establish GLP-1 receptor agonists as a novel therapeutic option for addiction.